https://scholars.lib.ntu.edu.tw/handle/123456789/532755
標題: | Risk factors and outcomes of Escherichia coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum-beta-lactamases | 作者: | UN-IN WU Wang J.-L. Chen W.-C. SHAN-CHWEN CHANG YEE-CHUN CHEN |
公開日期: | 2011 | 卷: | 30 | 期: | 1 | 起(迄)頁: | 33-39 | 來源出版物: | European Journal of Clinical Microbiology and Infectious Diseases | 摘要: | To determine whether there are differences in risk factors and outcomes among patients with E. coli bacteremia caused by strains that produce CTX-M or non-CTX-M extended-spectrum beta-lactamases. From 1 July 2005 to 30 June 2007, patients with positive blood culture of extended-spectrum β-lactamases (ESBL)-producing E. coli were reviewed. Sixty patients with ESBL-producing E. coli bacteremia were identified. These included 41 (68.3%) isolates with CTX-M β-lactamases. CTX-M-14 accounted for 31 (75.6%) and CTX-M-3 for 9 (22.0%) of the 41 CTX-M isolates. Patients with CTX-M strains were less likely, by univariate analysis, to have significant risk factors for infection including age?65 years, chronic renal insufficiency, ICU stay at bacteremia onset, central venous catheter use and mechanical ventilation. Multivariate analysis revealed that chronic renal failure and ICU stay were independent predictors. Antibiograms were similar for CTX-M and non-CTX-M producers except that CTX-M strains were significantly more susceptible to cefmetazole (92.7 vs 36.8%, p<0.0001). The overall mortality and length of hospitalization were not significantly different between the two groups. E. coli with CTX-M β-lactamases was more likely than non-CTX-M strains to invade non-compromised patients. There were no differences in clinical outcomes between the two groups. ? 2010 Springer-Verlag. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-78751567921&doi=10.1007%2fs10096-010-1048-2&partnerID=40&md5=ac6d75b2f9348ffaa9cbf3c0418af2d1 https://scholars.lib.ntu.edu.tw/handle/123456789/532755 |
ISSN: | 0934-9723 | DOI: | 10.1007/s10096-010-1048-2 | SDG/關鍵字: | amikacin; amoxicillin plus clavulanic acid; beta lactam antibiotic; beta lactamase CTX M; beta lactamase CTX M 14; beta lactamase CTX M 3; beta lactamase inhibitor; beta lactamase SHV; carbapenem derivative; cefazolin; cefmetazole; cefotaxime; ceftazidime; ceftriaxone; cephalosporin derivative; cephamycin; ciprofloxacin; ertapenem; extended spectrum beta lactamase; gentamicin; piperacillin plus tazobactam; quinoline derived antiinfective agent; unclassified drug; abdominal infection; adolescent; adult; antibiotic sensitivity; article; artificial ventilation; bacterial metabolism; bacterial strain; bacterial virulence; blood culture; central venous catheterization; chronic kidney failure; communicable disease; controlled study; enzyme synthesis; Escherichia coli infection; female; Gram negative sepsis; hospital infection; human; intensive care unit; length of stay; major clinical study; male; mortality; multiplex polymerase chain reaction; nonhuman; outcome assessment; priority journal; risk factor; strain difference; urinary tract infection; Adult; Aged; Aged, 80 and over; Bacteremia; beta-Lactamases; Escherichia coli; Escherichia coli Infections; Female; Humans; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Risk Factors; Treatment Outcome |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。